Study Sponsor:
Children's Oncology Group; National Cancer Institute (NCI)
Full IRB Study Title:
AAML 1331, A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid: A COG Group wide Phase III Study
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute,
330-543-3193 or email
research@akronchildrens.org